Shaun Cook, NP
Critical Care Medicine · Albany, GANPI 1134675531
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 381 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Among critical care medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 381 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Insmed, Inc.$713
- Boehringer Ingelheim$651
- Johnson & Johnson$473
- Regeneron Healthcare Solutions, Inc.$460
- AstraZeneca$455
- plus $3K from 27 others
What the payments were for
- Food & beverage$6,87893%
- Education$5017%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 109 | $1,498 |
| Insmed, Inc. | 29 | $713 |
| Boehringer Ingelheim | 37 | $651 |
| Johnson & Johnson | 26 | $473 |
| Regeneron Healthcare Solutions, Inc. | 18 | $460 |
| AstraZeneca(2 entities) | 28 | $455 |
| Grifols USA, LLC | 17 | $408 |
| Sanofi | 11 | $316 |
| Actelion Pharmaceuticals US, Inc. | 15 | $307 |
| Merck | 12 | $294 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $267 |
| Mallinckrodt Hospital Products Inc. | 5 | $246 |
| Bayer | 10 | $222 |
| United Therapeutics Corporation | 8 | $168 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Electromed, Inc. | 7 | $95 |
| Amgen | 3 | $83 |
| Baxter Healthcare | 4 | $80 |
| Mylan Specialty L.p. | 3 | $74 |
| Philips North America LLC | 3 | $64 |
| Verona Pharma, Inc. | 2 | $58 |
| Harmony Biosciences LLC | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Inspire Medical Systems, Inc. | 2 | $35 |
| CSL Behring | 1 | $31 |
| Phathom Pharmaceuticals, Inc. | 4 | $25 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Vifor Pharma, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Pfizer | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $16 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $15 |
How this compares
$7,379 in reported general payments places this provider in the 90th percentile of 265 critical care medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 26 | $305,140 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 346 | $261,847 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 99 | $68,460 |
| Dupixent SyringeDupilumab | 14 | $52,874 |
| Dupixent PenDupilumab | 15 | $51,210 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 74 | $40,251 |
| Spiriva RespimatTiotropium Bromide | 57 | $35,831 |
| Breo ElliptaFluticasone/Vilanterol | 78 | $35,813 |
| SymbicortBudesonide/Formoterol Fumarate | 101 | $27,026 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $23,199 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 656 | $16,108 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $13,026 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 58 | $9,769 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $8,332 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 16 | $6,410 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Combivent Respimat, Spiriva Respimat, Stiolto Respimat | $651 | $394,247183 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,498 | $326,287473 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $455 | $101,895216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 critical care medicine providers in Georgia.
Other critical care medicine in Albany
- James PalazzoloAlbany$16K
- Ramana RaoAlbany$13K
- Thomas UngarinoAlbany$12K
- Jyotir MehtaAlbany$12K
- Salman FidahusseinLagrange$852K
- Bruce FriedmanAugusta$629K
- Gregory MauldinSnellville$221K
- Ramzy RimawiAtlanta$72K
- Rafael Alba YunenBrunswick$58K
- April McDonaldGainesville$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.